OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OABIEMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e
OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
OABI(NASDAQ:OABI) EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9th with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their H.C. Wainwright representative, or email m
OmniAb Announces $30 Million Private Placement
OABIEMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expense
OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights
OABIEMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. “Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our team’s execution, and puts us on pace for one of our strongest years ever
Benchmark Reiterates Buy on OmniAb, Maintains $6 Price Target
OABIOmniAb Affirms FY2025 Sales Guidance of $20.00M-$25.00M vs $22.89M Est
OABIOmniAb Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $4.15M Miss $4.49M Estimate
OABIVERAXA Biotech Joins Forces with OmniAb to Develop Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
OABIRBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $4
OABIBenchmark Maintains Buy on OmniAb, Lowers Price Target to $6
OABIHC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
OABIOmniAb Expects 2025 Revenue Of $20M - $25M, Expects Cash Use To Be Lower Than Its Cash Use In 2024
OABIOmniAb Q4 2024 GAAP EPS $(0.12) Misses $(0.11) Estimate, Sales $10.80M Beat $10.13M Estimate
OABIBenchmark Reiterates Buy on OmniAb, Maintains $8 Price Target
OABIHC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
OABI